- Formulation Has Potential to Address Large Acute Pain Prescription Drug
LAVAL, QC, March 10 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that it has begun enrolling patients in its Phase III clinical trial
for its twice-daily, tramadol-acetaminophen combination product (study
"Tramadol-acetaminophen combination products have become widely
prescribed based on their ability to provide the analgesic potency of tramadol
and the rapid efficacy of acetaminophen, as well as their use in treating a
broad spectrum of pain types," said James R. Howard-Tripp, President and Chief
Executive Officer, Labopharm Inc. "Our formulation has the potential to be the
first twice-daily tramadol-acetaminophen product, as well as to compete in the
broader acute pain prescription drug market globally. Accordingly, it would be
an excellent complement to our once-daily tramadol product for the treatment
of persistent pain."
Currently marketed tramadol-acetaminophen combination products must be
administered four- to six-times per day. Labopharm believes that by metering
the release of both tramadol and acetaminophen from a single tablet using its
Contramid(R) controlled-release technology, its formulation has the potential
to offer enhanced patient compliance through twice-daily administration, as
well as a potentially improved side effect profile. More importantly, based on
its potential potency, efficacy, safety and convenience, the Company's novel
formulation of tramadol-acetaminophen could be well positioned as an
alternative to other prescription products for the treatment of mild to
moderate acute pain, including mild-opioids, tramadol, COX-2 inhibitors,
non-steroidal anti-inflammatory drugs (NSAIDs) and combination forms of these
Study 06CCL3-001 is a multi-centre, randomized, double-blind,
parallel-arm study that will compare the efficacy and safety of Labopharm's
twice-daily tramadol-acetaminophen combination product to placebo in the
treatment of acute low back pain. The study, which is being conducted at more
than 20 centers in the U.S. and Canada, has a treatment period of
approximately one week and is expected to include more than 250 patients.
About the Acute Pain Prescription Market
The number of prescriptions written for acute pain products
(mild-opioids, tramadol, COX-2 inhibitors, non-steroidal anti-inflammatory
drugs and combinations forms of these products) in the U.S. alone in 2007 grew
to 290 million and accounted for sales of US$9.0 billion.
About Tramadol-Acetaminophen Combination Products
Tramadol-acetaminophen combination products offer the analgesic strength
of tramadol and the rapid analgesia of acetaminophen in a single tablet.
Tramadol-acetaminophen combination products were first launched in 2001 in the
United States and in 2003 in other major markets and are indicated for the
short-term (five days or less) management of acute pain in the US and the
symptomatic treatment of moderate to severe pain in the rest of the world.
Tramadol-acetaminophen combination products are currently available only in
formulations that must be administered four- to six-times per day.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company also has a
robust pipeline of follow-on products in both pre-clinical and clinical
development. Labopharm's vision is to become a fully integrated,
international, specialty pharmaceutical company with the capability to
internally develop and commercialize its own products. For more information,
please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the outcomes of clinical trials, to the
regulatory process in various countries for the approval of the Company's
products and the successful commercialization of the products throughout the
world if they are approved. Investors should consult the Company's ongoing
quarterly filings and annual reports for additional information on risks and
uncertainties relating to these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. The Company
disclaims any obligation to update these forward-looking statements.
For further information:
For further information: At Labopharm: Mark D'Souza, Chief Financial
Officer, Tel: (450) 686-0207; At The Equicom Group: Jason Hogan, Media and
Investor Relations, Tel: (416) 815-0700, firstname.lastname@example.org; French: Eric
Bouchard, Tel: (514) 844-7997, email@example.com